Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: The spatiotemporal matching pattern of Ezrin/Periaxin involved in myoblast differentiation and fusion and Charcot-Marie-Tooth disease-associated muscle atrophy

Fig. 1

Combined gene therapy with Ezrin and L-periaxin repaired PNI-associated muscle atrophy. A Typical image of MyHC-I (NOQ) or MyHC-II (MY32) staining in the gastrocnemius muscle in the peroneal nerve injury (PNI) model. Red fluorescence indicates MyHC-I; green fluorescence indicates MyHC-II; DAPI indicates the nucleus. B Quantitative assay for total MyHC-positive myofibers in the above images. Total MyHC + myofiber numbers = MyHC-I + MyHC-II myofiber numbers. C Quantitative assay for MyHC-I- or MyHC-II-positive myofibers in the above images. D The ratio of myofiber size in MyHC-I- or MyHC-II-positive myofibers in the PNI and treatment groups was normalized to that in the sham group. n = 6, *P < 0.05 vs. Sham + Ad-Null group; #P < 0.05 vs. PNI + Ad-Null group; &P < 0.05 vs. PNI + Ad-Null group; $P < 0.05 vs.PNI + Ad-Null group; @P < 0.05 vs. Ad-Ezrin + PNI group; ^P < 0.05 vs. Ad-Ezrin + PNI group

Back to article page